A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and With MVA CS
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 试验地点
- 1
- 主要终点
- Safety assessment of new candidate malaria vaccines ChAd63 CS
研究概览
简要总结
This is an open label phase I study, to assess the safety of a novel malaria vaccine, AdCh63 CS, simian adenovirus encoding Plasmodium falciparum liver stage antigen, Circumsporozoite protein. All volunteers recruited will be healthy adults. They will be primed with various doses of AdCh63 CS administered intramuscularly. Some of the volunteers will receive a booster vaccination with MVA CS administered via intramuscular route. Safety data will be collected for each vaccination regimen. Secondary aim of this study will be to assess the immune responses generated by vaccination.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 50 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- •History of clinical P. falciparum malaria
- •Travel to a malaria endemic region during the study period or within the preceding six months with a significant risk of malaria exposure.
- •Participation in another research study involving an investigational product in the 30 days preceding enrolment, or planned use during the study period.
- •Prior receipt of an investigational malaria vaccine or any other investigational vaccine likely to impact on interpretation of the trial data.
- •Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate.
- •Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical steroids are allowed)
- •Pregnancy, breast feeding or intention to become pregnant during the study
- •History of allergic disease or reactions likely to be exacerbated by any component of the vaccine e.g. egg products, Kathon.
- •History of clinically significant contact dermatitis.
- •Any history of anaphylaxis post vaccination.
- •History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).
- •History of serious psychiatric condition that may affect participation in the study.
- •Any other serious chronic illness requiring hospital specialist supervision.
- •Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week.
- •Suspected or known injecting drug abuse in the 5 years preceding enrolment.
- •Seropositive for hepatitis B surface antigen (HBsAg).
- •Seropositive for hepatitis C virus (antibodies to HCV).
- •Any clinically significant abnormal finding on biochemistry or haematology blood tests, urinalysis or clinical examination.
- •Any other significant disease, disorder or finding which may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data.
结局指标
主要结局
Safety assessment of new candidate malaria vaccines ChAd63 CS
时间窗: Participants will be followed for the duration of the study, an expected average of 12 months
To assess the safety of new candidate malaria vaccines ChAd63 CS administered alone and with MVA CS in a prime-boost regime to healthy volunteers by recording local and systemic solicited and unsolicited adverse events.
次要结局
- Assessment of immune response induced by vaccination(Participants will be followed for the duration of the study, an expected average of 12 months)